Journal
Breast cancer research
Publication Date
12-21-2025
Volume
28
Issue
1
First Page
18
Document Type
Open Access Publication
DOI
10.1186/s13058-025-02168-6
Rights and Permissions
Bhave, M., Jhaveri, K.L., Kaufman, P.A. et al. Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. Breast Cancer Res 28, 18 (2026). https://doi.org/10.1186/s13058-025-02168-6 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Bhave, Manali; Ma, Cynthia X; and et al., "Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: Results from the phase 1a/1b EMBER study." Breast cancer research. 28, 1. 18 (2025).
https://digitalcommons.wustl.edu/oa_4/6772
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
